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how the concept and principles of software engineering and adopting their best 
practices in model development can increase model transparency and our confi-
dence that our models perform as expected. We will also compare the advantages 
and disadvantages of using spreadsheets versus other programming languages. 
Briefly, the primary advantage of the spreadsheet is that it’s universally available 
and accessible to all. It’s universal in that a spreadsheet is available on most com-
puters. It’s accessible in that everyone can open the model, inspect it, and use it. 
Beyond these advantages, the structure of the spreadsheet challenges our model 
code to be intention revealing and transparent. For example, generating an audit 
trail showing the history of what changes were made, when, and by who is not 
possible with spreadsheet files. Moreover, the spreadsheet does not have available 
standard software tools for developing test suites. A test suite represents a series 
of tests that must be passed to confirm software performs as expected. For models, 
this would mean the test suite confirms a model computes what it purports to com-
pute. Hence, test suites serve a critical and foundational function in the lifecycle of 
modern software development and can serve a similar role in pharmacoeconomic 
model development. In summary, adopting traditional programming languages and 
their software engineering support tools offers an opportunity to increase model 
transparency compared with spreadsheets. Reimbursement agencies should con-
sider broadening their software guidances to include non-spreadsheet programming 
languages to increase model transparency and our confidence that pharmacoeco-
nomic models perform as expected.
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The end product of EQ-5D valuation studies is an algorithm describing, on aver-
age, the utility decrements associated with each dimension and level of problems 
within the EQ-5D descriptive system, and potentially a range of interaction effects 
between dimensions and levels. Standard methods for eliciting the preference data 
upon which these algorithms are based (time trade-off, discrete choice experiment, 
standard gamble, visual analogue scale) vary considerably in approach, but have 
in common an aim to ‘uncover’ these preferences by asking survey respondents to 
evaluate a sub-set of EQ-5D health states, and then using their responses to infer 
the relative importance to them of the specific dimensions and levels. An alterna-
tive approach, which has never been explored, is to directly ask people to construct 
their own personal utility functions. Instead of asking people to value a selection of 
EQ-5D states, and to infer their utility functions with respect to EQ-5D dimensions 
and levels from their responses, this approach involves directly asking people about 
the relative importance to them of dimensions, levels and interactions between 
them. In this presentation, we will describe the development of an innovative set 
of questions designed to directly elicit personal utility functions from members of 
the general public. The approach is informed by “swing weighting” techniques in the 
multi-criteria decision analysis literature and by existing direct valuation methods 
such as the short form individual quality of life measure. We will summarise the 
results of a feasibility study which tested the acceptability of the questions, and will 
show how the results can be used to generate EQ-5D values. We will also discuss the 
research that is required to further refine and operationalise the method.
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Objectives: Cardiac rhythm management devices (CRMD’s) have proven their clini-
cal effectiveness for patients with heart rhythm disorders. Little is known about safety 
and complication rates during implantations of these devices. This study demon-
strated the major ant the minor complications related to implantations of CRMD’s, 
and estimated the additional hospital stay and cost associated with managing these 
adverse events. MethOds: During a period of one year in total 464 consecutive recipi-
ents were subjected to CRMD’s implantation and furthermore were recruited and 
followed up for 2 years. Finally, data were analyzed for 398 patients who completed 
the two year’s follow up, resulting in a total of 796 patient-years. Results: From the 
201 patients with initial pacemaker (PM) implantations, 6 (2,99 %) patients had seven 
adverse events, six major and one minor (5 patients had lead’s dislodgement, 1 of 
them twice (minor adverse events) and 1 patient developed pocket infection (major 
adverse event)), while from the 117 PMs replacements 1 (0,85 %) patient developed 
a major adverse event a pocket erosion. 2 patients with minor adverse event (1 with 
an initial PM and 1 with replacement) died before they complete the follow up from 
reasons unrelated to cardiac causes. There weren’t any adverse event neither in 
initial implantations (69 patients) nor in replacements (11 patients) of implantable 
cardioverter defibrillator (ICD). The average prolongation of the hospital stay was 7 
days ranging from 1 to 35 days, resulting in 17.411 € of total additional direct hospital 
cost. cOnclusiOns: This study provides relatively low rates of adverse events in 
impacts on data analysis/results along with cost impact. As estimated by the Data 
Warehousing Institute, the costs of low quality data exceeds $600 billion annually. 
Data cleaning process includes querying for errors, typos, outliers, out-of-range 
responses, missing data, deviations, etc. Paper: query data for erroneous/out-of 
range values; these values need to be cross-checked with original paper form to 
identify if error is associated with patient entry or data entry staff. If associated with 
patient entry, it may need to be set as missing. When original paper is lost, values 
may need to be set to missing as accuracy cannot be confirmed. Time/dates may be 
out-of-range or missing, which require cross-checking with original paper. If time/
date cannot be confirmed, the entire entry may need to be set as missing. Missing 
values in data need to be identified and cross-checked with original paper to confirm 
if value was skipped by patient or by data entry staff. ePRO: can be implemented to 
prevent entry of out-of range values; includes time/date stamps; patient direct data 
entry eliminates error by data entry staff; can be programmed to not allow skipped 
responses to prevent missing data responses. End-of-study time is precious to the 
pharma industry where results need to be analyzed for submissions. Data cleaning 
with paper can be labor intensive and ePRO can save time with preventing errors 
from occurring, reducing time needed for data cleaning.
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Objectives: The global economic crisis imposes severe restrictions on healthcare 
budgets, limiting the coverage of new interventions, even when they are cost-effec-
tive. Our objective was to develop a tool that can assist decision-makers in compar-
ing the impact of medical intervention alternatives on the entire target population, 
under a pre-specified budget constraint. MethOds: We illustrated the tool by using 
a target population of 1,000 patients, and a budget constraint of $1,000,000. We com-
pared two intervention alternatives: the current practice that costs $1,000 and adds 
0.5 quality-adjusted-life-years (QALYs) per patient and a new technology that costs 
100% more, and provides 20% more QALYs per patient. We also developed a formula 
for defining the maximum premium price for a higher-cost/higher-effectiveness 
intervention that can justify its adoption under a constrained budget. Results: 
Using the new therapy will result in a loss of 300 QALYs, compared to the lower-
cost, lower-effective intervention, despite a favorable incremental cost-effectiveness 
ratio (ICER) of $10,000. The maximum price for the higher-efficacy therapy that 
will preserve the target population outcomes is 20% higher than the lower-cost 
therapy. cOnclusiOns: Although an intervention associated with higher costs 
and higher efficacy may have an acceptable ICER, it could provide inferior outcomes 
in the target population under budget constraints, depending on the relative effec-
tiveness and costs of the interventions. The cost premium that can be justified for 
a higher-efficacy intervention is directly correlated to its effectiveness premium. 
Using the proposed tool may assist decision-makers in improving overall healthcare 
outcomes, especially in times of economic downturn.
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While some have fully embraced and incorporated ePROs/eCOAs into protocol 
designs, many continue to use paper PROs/COAs. This conceptual paper explores rea-
sons for paper PRO/COA continued use, focusing on how PROs can be integrated into 
the electronic trial solution to reduce the burden to patients/participants, sites, and 
clinical teams in setting up, maintaining, and closing out a clinical trial. Associated 
risks and mitigation strategies will be identified in transitioning to ePRO/eCOA 
collection modes. Strategies recommended for successful transition to integrated 
electronic PRO/COA solutions will be discussed. Integration of ePRO/eCOA provides 
several benefits over paper, including improved compliance and higher data quality. 
Comparing the advantages of electronically captured PRO/COA data vs. paper, the 
benefits of ePRO/eCOA far outweigh those of paper. Combine this with the support 
and advocacy of ePRO/eCOA in clinical trials by regulatory authorities and a shift of 
the general population towards electronic devices; it raises the question why all clini-
cal trials are not using ePRO/eCOA to optimize the integrity of data and trial results. 
Common obstacles in the selection of a PRO/COA electronic data collection mode 
include: paper instruments designed for a paper world, inability to determine true 
risks, unknown total cost of electronic vs. paper administration, instrument author 
has sometimes costly requirements for migration, unclear translation expectations, 
and fear of the unknown. An assessment of methods to facilitate the transition to 
electronic data capture will be performed. Examples include use of items/instruments 
that are appropriate for electronic platforms and easily migrated and site and patient 
training plans. In this age of technological advancements, including an integration 
plan in clinical trials is important to mitigate potential risks and minimize the burden 
to clinical trial staff and participants. Detailing this up front can help to alleviate many 
of the obstacles in the transition from paper to electronic PRO/COA.
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The spreadsheet dominates the pharmacoeconomics field as the software platform 
of choice for programming pharmacoeconomic models that are submitted to reim-
bursement agencies worldwide. Arguably, the spreadsheet represents a poor choice 
for model development and implementation as standard software development 
tools to manage spreadsheet quality are non-existent. This paper will demonstrate 
